Exportin 1抑制剂selinexor治疗复发性妇科恶性肿瘤的2期研究
本研究为2期试验,评估口服Exportin 1抑制剂selinexor在经多线治疗的复发性卵巢癌、子宫内膜癌和宫颈癌患者中的疗效与安全性。114例患者接受不同剂量方案,主要终点疾病控制率分别为卵巢癌30%、子宫内膜癌35%、宫颈癌24%。常见3/4级不良事件为血小板减少、乏力、贫血、恶心和低钠血症。
要点
- selinexor单药在经多线治疗的复发性卵巢癌和子宫内膜癌中显示疾病控制活性。
- 卵巢癌患者每周一次50 mg/m²方案较每周两次方案高效性相似且高级别不良事件更少。
- 常见3/4级不良事件包括血小板减少17%、乏力14%、贫血10%、恶心9%、低钠血症9%。
核心结论
- selinexor单药在经多线治疗的复发性卵巢癌和子宫内膜癌患者中显示疾病控制活性。
- 不良反应与剂量水平和治疗频率相关,类似既往报道,可逆且可通过支持治疗减轻。
研究设计与样本
- 2期试验,纳入114例复发性妇科恶性肿瘤患者,其中卵巢癌66例、子宫内膜癌23例、宫颈癌25例。
- 患者接受selinexor 35或50 mg/m²每周两次或50 mg/m²每周一次,4周为一周期。
- 主要终点为疾病控制率,包括完全缓解、部分缓解或疾病稳定≥12周;次要终点为无进展生存期、总生存期和安全性。
主要发现
- 总体疾病控制率为30%,其中卵巢癌30%、子宫内膜癌35%、宫颈癌24%。
- 确诊部分缓解率在卵巢癌、子宫内膜癌和宫颈癌分别为8%、9%和4%。
- 卵巢癌、子宫内膜癌和宫颈癌的中位无进展生存期分别为2.6、2.8和1.4个月,中位总生存期分别为7.3、7.0和5.0个月。
- 卵巢癌、子宫内膜癌和宫颈癌患者既往中位治疗方案数分别为6(范围1-11)、2(范围1-5)和3(范围1-6)。
- 常见3/4级不良事件为血小板减少17%、乏力14%、贫血10%、恶心9%和低钠血症9%。
关键数值与推荐
- 疾病控制率定义包括完全缓解、部分缓解或疾病稳定≥12周。
- 给药方案包括selinexor 35或50 mg/m²每周两次或50 mg/m²每周一次,4周为一周期。
临床怎么用
- selinexor单药可作为经多线治疗的复发性卵巢癌和子宫内膜癌患者的疾病控制选择。
- 卵巢癌患者采用50 mg/m²每周一次方案可能减少高级别不良事件且保持疗效相似。
- 用药期间需监测血小板减少、乏力、贫血、恶心和低钠血症等不良事件,并给予支持治疗。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selinexor is an oral inhibitor of the nuclear export protein Exportin 1 (XPO1) with demonstrated antitumor activity in solid and hematological malignancies. We evaluated the efficacy and safety of selinexor in heavily pretreated, recurrent gynecological malignancies. METHODS: In this phase 2 trial, patients received selinexor (35 or 50 mg/m2 twice-weekly [BIW] or 50 mg/m2 once-weekly [QW]) in 4-week cycles. Primary endpoint was disease control rate (DCR) including complete response (CR), partial response (PR) or stable disease (SD) ≥12 weeks. Secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. RESULTS: 114 patients with ovarian (N = 66), endometrial (N = 23) or cervical (N = 25) cancer were enrolled. Median number of prior regimens for ovarian, endometrial and cervical cancer was 6 (1-11), 2 (1-5), and 3 (1-6) respectively. DCR was 30% (ovarian 30%; endometrial 35%; cervical 24%), which included confirmed PRs in 8%, 9%, and 4% of patients with ovarian, endometrial, and cervical cancer respectively. Median PFS and OS for patients with ovarian, endometrial and cervical cancer were 2.6, 2.8 and 1.4 months, and 7.3, 7.0, and 5.0 months, respectively. Common Grade 3/4 adverse events (AEs) were thrombocytopenia (17%), fatigue (14%), anemia (10%), nausea (9%) and hyponatremia (9%). Patients with ovarian cancer receiving 50 mg/m2 QW had fewer high-grade AEs with similar efficacy as BIW treatment. CONCLUSIONS: Selinexor demonstrated single-agent activity and disease control in patients with heavily pretreated ovarian and endometrial cancers. Side effects were a function of dose level and treatment frequency, similar to previous reports, reversible and mitigated with supportive care.
引用
- Vergote IB, Lund B, Peen U, et al. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecol Oncol. 2019. PMID: 31822399. doi:10.1016/j.ygyno.2019.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。